Key Takeaways TFX Q4 adjusted EPS rose 1% to $1.93 but missed estimates by 48.3%, with revenues below consensus. Teleflex's gross margin fell 678 bps to 54% as costs jumped 51%, pressuring operating profit. TFX expects 2026 GAAP revenue growth of 14.4-15.4% and adjusted EPS of $6.25-$6.55. Teleflex Incorporated (TFX) posted fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $1.93, up 1% from the year-ago quarter’s figure. The metric missed the Zacks Consensus Estimate by 48. ...

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences comp ...

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zynex, Inc. (OTCMKTS: ZYXIQ) securities between February 25, 2021 and December 15, 2025. Zynex is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis, and cardiac monitoring. For more information, submit a form, email attorney Aaron Dumas ...

Core Insights - Treace Medical Concepts, Inc. reported financial results for Q4 and full-year 2025, highlighting a shift in product sales and expectations for future growth [1][3][4]. Financial Performance - Q4 2025 revenue was $62.5 million, a 9% decrease from $68.7 million in Q4 2024, primarily due to a shift towards lower-priced bunion kits [4]. - Gross profit for Q4 2025 was $50.4 million, with a gross margin of 80.6%, slightly down from 80.7% in Q4 2024 [4]. - Total operating expenses in Q4 2025 were $56.3 million, up 1% from $55.7 million in Q4 2024 [5]. - The net loss for Q4 2025 was $(9.4) million, or $(0.15) per share, compared to a net loss of $(0.5) million, or $(0.01) per share, in Q4 2024 [5]. - Adjusted EBITDA for Q4 2025 was $6.2 million, down from $11.1 million in Q4 2024 [5]. Full-Year Results - Full-year 2025 revenue was $212.7 million, a 2% increase from $209.4 million in 2024 [6]. - Gross profit for the full year was $169.8 million, with a gross margin of 79.8%, down from 80.4% in 2024 [6]. - Total operating expenses for 2025 were $223.9 million, slightly down from $224.0 million in 2024 [6]. - The full-year net loss was $(59.0) million, or $(0.93) per share, compared to $(55.7) million, or $(0.90) per share, in 2024 [7]. - Adjusted EBITDA loss for 2025 was $(3.9) million, significantly improved from $(11.0) million in 2024 [7]. Operational Highlights - The company increased its active surgeon base by 202, ending 2025 with 3,337 active surgeons, a 6% increase year-over-year [8]. - The company broadened its global patent portfolio to 135 granted patents and 199 pending applications [8]. Cash Flow and Liquidity - Cash, cash equivalents, and marketable securities totaled $48.4 million as of December 31, 2025 [9]. - The company reduced cash usage by 46% to $27.3 million in 2025 compared to $50.5 million in 2024 [8][9]. 2026 Financial Outlook - The company projects full-year 2026 revenue guidance of $200 million to $212 million, indicating a decline of 6% to 0% compared to 2025 [10]. - Expected Adjusted EBITDA loss for 2026 is projected to be between $(4.0) million and $(6.0) million [10]. - Anticipated reduction in cash usage for 2026 is approximately 50% compared to 2025 [10].

www.OrthoPediatrics.com Disclaimer Forward-Looking Statements 2026 Investor Presentation All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "ma ...

Alphatec Holdings, Inc. (NASDAQ:ATEC) is one of the best small-cap stocks with huge growth potential. On TD Cowen cut the price target on Alphatec Holdings, Inc. (NASDAQ:ATEC) to $20 from $27 on January 26, maintaining a Buy rating on the shares after a transfer of coverage. The firm sees the company’s “growth vectors” as not being fully appreciated in Street expectations, which creates potential upside to estimates. Alphatec Holdings, Inc. (NASDAQ:ATEC) also received a rating update from Lake Street on ...

Boston Scientific Corporation (NYSE:BSX) is one of the best strong buy healthcare stocks to invest in. Boston Scientific Corporation (NYSE:BSX) announced on February 23 the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Was Jim Cramer Right About Boston Scientific Corporation (BSX)? The company also received several rating updates following its fiscal Q4 and full-year earnings release, with BTIG reaffirming a Buy rating on the stock with a price targe ...

Insulet Corporation (NASDAQ:PODD) is among the 10 High Growth S&P 500 Stocks to Buy Now. Truist Lowers its Price Target on Insulet Corporation (PODD) to $360 and Maintains a Buy Rating Truist on February 19, 2026, lowered its price target on Insulet Corporation (NASDAQ:PODD) to $360 from $390 and maintained a Buy rating. The firm said Insulet delivered another strong Q4 beat, supported by broad global strength in Omnipod 5 as the company builds on its first-mover advantage in Type 2 diabetes and leverage ...

建行北京市分行创新打造科技金融"星火+"党建品牌，全力赋能首都科技成果转化与产业化发展。图为 该行信贷支持的赛诺威盛科技（北京）股份有限公司员工在CT设备生产车间作业。 ...

Core Insights - The rapid adoption of generative AI is transforming investment strategies, shifting focus from semiconductor manufacturers to companies across various sectors that are integrating AI into their operations and products [1] - Generative AI has reached 50% penetration in U.S. households within three years, significantly faster than previous technologies like the postal system and the Internet [1] Investment Landscape - Alger's research categorizes the AI landscape into "Enablers," which include hardware and software providers, and "Adopters," which are companies integrating AI to enhance products and improve productivity [1] - Investment opportunities are emerging not only in infrastructure but also in diverse sectors such as medical devices, financial services, advertising, aerospace, and cybersecurity, all leveraging AI for various applications [1] Sector Applications - Medical device companies are utilizing AI for earlier disease detection, while financial services firms are automating compliance processes to enhance margins [1] - Other sectors are deploying AI for personalized content in advertising, threat detection in aerospace and defense, and automated incident response in cybersecurity [1] - Companies in customer service, logistics, and waste management are also adopting AI to streamline workflows and reduce costs, focusing on internal productivity improvements [1] Investment Fund - The Alger AI Enablers & Adopters ETF (ALAI) invests in both enablers and adopters of AI technology, with a 0.55% expense ratio and launched in April 2024 [1] - Top holdings in the ETF include major technology firms such as Microsoft, Amazon, and Alphabet, alongside semiconductor manufacturers and emerging AI-focused companies [1]